As the European markets navigate mixed performances, with indices like Germany’s DAX gaining slightly and others such as France’s CAC 40 experiencing declines, investors are closely watching policy signals from the European Central Bank. In this context, penny stocks—often representing smaller or newer companies—remain a relevant investment area despite their somewhat outdated label. This article will explore three noteworthy penny stocks in Europe that may offer unique opportunities by combining financial strength with potential growth prospects.
Top 10 Penny Stocks In Europe
| Name | Share Price | Market Cap | Rewards & Risks |
| Ariston Holding (BIT:ARIS) | €4.75 | €1.64B | ✅ 4 ⚠️ 2 View Analysis > |
| Orthex Oyj (HLSE:ORTHEX) | €4.70 | €83.47M | ✅ 4 ⚠️ 1 View Analysis > |
| Lucisano Media Group (BIT:LMG) | €1.00 | €14.86M | ✅ 4 ⚠️ 5 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 2 View Analysis > |
| Angler Gaming (DB:0QM) | €0.37 | €221.21M | ✅ 3 ⚠️ 3 View Analysis > |
| Libertas 7 (BME:LIB) | €3.06 | €64.91M | ✅ 3 ⚠️ 3 View Analysis > |
| Hultstrom Group (OM:HULT B) | SEK3.10 | SEK188.6M | ✅ 2 ⚠️ 2 View Analysis > |
| ForFarmers (ENXTAM:FFARM) | €4.315 | €381.38M | ✅ 4 ⚠️ 1 View Analysis > |
| Deceuninck (ENXTBR:DECB) | €2.26 | €312.38M | ✅ 3 ⚠️ 1 View Analysis > |
| Netgem (ENXTPA:ALNTG) | €0.77 | €25.79M | ✅ 2 ⚠️ 2 View Analysis > |
Click here to see the full list of 291 stocks from our European Penny Stocks screener.
Let's dive into some prime choices out of the screener.
AFYREN SAS (ENXTPA:ALAFY)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: AFYREN SAS offers biobased products as alternatives to petroleum-based molecules in France, with a market cap of €72.72 million.
Operations: The company generates its revenue primarily from the Chemicals segment, which amounts to €2.70 million.
Market Cap: €72.72M
AFYREN SAS, with a market cap of €72.72 million, is navigating the penny stock landscape by leveraging its innovative biobased products as alternatives to petroleum-based molecules. Despite being unprofitable and lacking significant revenue (€3M), it has a strong cash position with assets exceeding liabilities and no meaningful shareholder dilution recently. The company has partnered with Esse Skincare to introduce bio-based propionic acid for skincare, highlighting its commitment to sustainability and innovation. A recent private placement raised nearly €23 million, indicating investor confidence despite high share price volatility and ongoing financial challenges.
- Jump into the full analysis health report here for a deeper understanding of AFYREN SAS.
- Gain insights into AFYREN SAS' future direction by reviewing our growth report.
écomiam (ENXTPA:ALECO)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: écomiam SA operates stores selling food products in France and has a market cap of €9.35 million.
Operations: The company's revenue is generated entirely from its retail grocery store operations, amounting to €39.49 million.
Market Cap: €9.35M
écomiam SA, with a market cap of €9.35 million, operates in the retail grocery sector, generating €39.49 million in revenue from its stores across France. While currently unprofitable and not expected to achieve profitability within the next three years, it maintains a stable financial position with short-term assets (€8.8M) exceeding both its short-term (€4.2M) and long-term liabilities (€2M). The company has managed to reduce its debt significantly over five years and retains a cash runway of 1.7 years if cash flow continues to decline at historical rates, without significant shareholder dilution recently observed.
- Navigate through the intricacies of écomiam with our comprehensive balance sheet health report here.
- Assess écomiam's future earnings estimates with our detailed growth reports.
Navigo Invest (OM:NAVIGO STAM)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Navigo Invest AB (publ) is a private equity and venture capital firm that focuses on various investment stages including buyouts, early and later stage, acquisition, growth capital, middle markets, turnaround and mature stage investments, with a market cap of SEK363.23 million.
Operations: Navigo Invest generates revenue primarily from Chemgroup (SEK281.08 million), The Vinga Group (SEK219.62 million), The Calorimeter (SEK90.83 million), and The Geogroup (SEK41.41 million).
Market Cap: SEK363.23M
Navigo Invest AB, with a market cap of SEK363.23 million, has shown significant revenue growth, reporting SEK152.21 million for Q3 2025 compared to SEK117.81 million the previous year. Despite being unprofitable and having a negative return on equity (-18.27%), the company has reduced its debt-to-equity ratio from 309.8% to 10.9% over five years and maintains a satisfactory net debt-to-equity ratio of 8.5%. Its short-term assets cover both short- and long-term liabilities, providing financial stability alongside a cash runway exceeding three years due to positive free cash flow growth of 44.1% annually.
- Click to explore a detailed breakdown of our findings in Navigo Invest's financial health report.
- Understand Navigo Invest's earnings outlook by examining our growth report.
Turning Ideas Into Actions
- Click through to start exploring the rest of the 288 European Penny Stocks now.
- Looking For Alternative Opportunities? AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if AFYREN SAS might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com